Evidence map›Paper›PMID 36669876›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2023

Cannabinoid Tolerance in S426A/S430A x

Mary K Piscura, Diana E Sepulveda, Malabika Maulik, Josée Guindon, Angela N Henderson-Redmond, Daniel J Morgan

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Mechanisms of cannabinoid tolerance.Biochemical pharmacology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mary K PiscuraDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas.ORCID 0000-0002-1791-2933
Diana E SepulvedaDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas.
Malabika MaulikDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas.
Josée GuindonDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas.
Angela N Henderson-RedmondDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas morganda@marshall.edu redmonda@marshall.edu.
Daniel J MorganDepartment of Biomedical Sciences, Marshall University, Huntington, West Virginia (M.K.P., M.M., A.N.H.-R., D.J.M.); Department of Pharmacology (D.E.S.) and Graduate Program in Anatomy (M.K.P.), Penn State University College of Medicine, Hershey, Pennsylvania; and Department of Pharmacology and Neuroscience (J.G.) and Center of Excellence for Translational Neuroscience and Therapeutics (J.G.), Texas Tech University Health Sciences Center, Lubbock, Texas.
Texas Tech University · US

Funding

Mechanisms of cannabinoid toleranceR01DA044999 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GUINDON, JOSEE, MORGAN, DANIEL J · 2018 to 2022
$2.4M
NIDA NIH HHS R01 DA044999
6 · The paper itself

Abstract

Tolerance to compounds that target G protein-coupled receptors (GPCRs), such as the cannabinoid type-1 receptor (CB

Indexed as

CannabinoidsAnalgesicsAnimalsbeta-Arrestin 2CyclohexanolsDronabinolFemaleMaleMiceMice, KnockoutReceptor, Cannabinoid, CB1Receptors, Cannabinoid3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolAnalgesicsbeta-Arrestin 2CannabinoidsCyclohexanolsDronabinolReceptor, Cannabinoid, CB1Receptors, Cannabinoid

Identifiers

PMID36669876
PMCPMC10029824
OpenAlexW4317600108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.